Adaptimmune Therapeutics plc (ADAP)
NASDAQ: ADAP · Real-Time Price · USD
0.2765
-0.0030 (-1.07%)
At close: Jul 21, 2025, 4:00 PM
0.2800
+0.0035 (1.27%)
Pre-market: Jul 22, 2025, 8:12 AM EDT

Company Description

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom.

It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer.

The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520).

It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos’ decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center.

Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Adaptimmune Therapeutics plc
Adaptimmune Therapeutics logo
CountryUnited Kingdom
Founded2008
IPO DateMay 6, 2015
IndustryBiotechnology
SectorHealthcare
Employees506
CEOAdrian G. Rawcliffe

Contact Details

Address:
60 Jubilee Avenue, Milton Park
Abingdon, OX14 4RX
United Kingdom
Phone44 12 3543 0000
Websiteadaptimmune.com

Stock Details

Ticker SymbolADAP
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001621227
CUSIP Number00653A107
ISIN NumberUS00653A1079
SIC Code2836

Key Executives

NamePosition
Adrian G. RawcliffeChief Executive Officer and Director
William C. A. Bertrand Jr., Esq., J.D.Chief Operating Officer and Chief Compliance Officer
Cintia Piccina Pharm.D.Chief Commercial Officer
Dr. Helen Katrina Tayton-Martin MBA, Ph.D.Co-Founder
Joanna Brewer Ph.D.Chief Scientific Officer
Dr. Juli P. Miller Ph.D.Vice President of Corporate Affairs and Investor Relations
Kerry SharpSenior Vice President and General Counsel
Dana LynchSenior Director of Corporate Communications
John LungerChief Patient Supply Officer
Dr. Elliot Norry B.A., M.D.Chief Medical Officer

Latest SEC Filings

DateTypeTitle
Jul 17, 20258-KCurrent Report
May 29, 20258-KCurrent Report
May 15, 2025SCHEDULE 13G/AFiling
May 13, 202510-QQuarterly Report
May 13, 20258-KCurrent Report
May 1, 20258-KCurrent Report
Apr 25, 2025ARSFiling
Apr 25, 2025DEF 14AOther definitive proxy statements
Apr 18, 2025S-3Registration statement under Securities Act of 1933
Apr 15, 2025PRE 14AOther preliminary proxy statements